Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Hovione","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury\u00ae for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"PORTUGAL","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Hovione","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hovione Completes its Phase 2 Clinical Trial of the First Minocycline Ophthalmic","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"PORTUGAL","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"Hovione","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"PORTUGAL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Hovione","sponsor":"Zerion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zerion Pharma and Hovione Extend Partnership to Cover Use of The Dispersome\u00ae Technology Platform in Nutraceuticals","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"PORTUGAL","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Hovione

    Menu

    Hovione

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Hovione

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Portugal
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zerion Pharma and Hovione Extend Partnership to Cover Use of The Dispersome® Technology Platform in Nutraceuticals

              Details:

              Under their collaboration, Hovione and Zerion will now upscale and develop commercial formulations of the beta-lactoglobulin or BLG using the Dispersome® platform and make Lacprodan products available for distribution by partners globally.

              Lead Product(s): Beta-lactoglobulin

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Zerion Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Expanded Collaboration August 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hovione

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Portugal
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

              Details:

              Under the license agreement, JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization.

              Lead Product(s): JX08

              Therapeutic Area: Ophthalmology Product Name: JX08

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ji Xing Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement May 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hovione

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Portugal
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hovione Completes its Phase 2 Clinical Trial of the First Minocycline Ophthalmic

              Details:

              This is the first dry eye therapy targeting MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic and the first and only ophthalmic formulation of minocycline in clinical development, contingently named Meizuvo®.

              Lead Product(s): Minocycline Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: HY02

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hovione

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Portugal
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19

              Details:

              The partnership aims to significantly ramp up the production output of Captisol®. Captisol®, a Ligand product and a chemically modified cyclodextrin proven to improve the solubility and stability of drugs.

              Lead Product(s): Modified Cyclodextrin

              Therapeutic Area: Infections and Infectious Diseases Product Name: Captisol

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership September 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY